title: Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
abstract: OBJECTIVE
  To examine the trajectory of changes in body composition and metabolic profile in men who receive androgen-deprivation therapy (ADT) for prostate cancer.
  
  
  METHODS
  Prospective longitudinal design with repeated measures.
  
  
  METHODS
  Urban medical center in the southwestern United States.
  
  
  METHODS
  55 men starting radiation therapy for prostate cancer.
  
  
  METHODS
  Changes in the parameters of metabolic syndrome were estimated with ADT (n=31) and non-ADT (n=24) groups by repeated-measures analysis of variance implemented by general linear mixed-effects models. Models included interactions between groups and follow-up time to test differences between the groups.
  
  
  METHODS
  Body composition and metabolic variables.
  
  
  RESULTS
  The ADT group demonstrated a transient increase in waist circumference at the nine-month time point and significant changes in measures of insulin resistance were noted at the three month point. Values for diastolic and systolic blood pressure, plasma glucose, high-density lipoprotein, and triglycerides were not altered for either group. Differences in metabolic variables or measures of body composition did not differ significantly between the groups.
  
  
  CONCLUSIONS
  The findings demonstrate the development of insulin resistance in men receiving ADT as early as three months after starting ADT.
  
  
  CONCLUSIONS
  Addressing survivorship concerns can lead to the development of nursing interventions designed to reduce adverse effects associated with ADT.
authors.affiliation: Division of Hematology-Oncology, Health Care System in Arizona.
authors.forename: Joanne M
authors.initials: JM
authors.lastname: Harrington
authors.affiliation: Phoenix Veterans Affairs, Health Care System in Arizona.
authors.forename: Dawn C
authors.initials: DC
authors.lastname: Schwenke
authors.affiliation: College of Nursing and Health Innovation, Arizona State University.
authors.forename: Dana R
authors.initials: DR
authors.lastname: Epstein
authors.affiliation: School of Nursing, Duke University, Durham, NC.
authors.forename: Donald E
authors.initials: DE
authors.lastname: Bailey
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing / Q000532:radiotherapy; D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000728:Androgens / Q000502:physiology; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition / Q000187:drug effects*; D003131:Combined Modality Therapy; D015897:Comorbidity; D018450:Disease Progression; D005215:Fasting / Q000097:blood; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D006801:Humans; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D024821:Metabolic Syndrome / Q000139:chemically induced / Q000453:epidemiology* / Q000451:nursing; D008875:Middle Aged; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing / Q000532:radiotherapy; D056128:Obesity, Abdominal / Q000139:chemically induced; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000451:nursing / Q000532:radiotherapy
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D001786:Blood Glucose; D008055:Lipids; D007987:Gonadotropin-Releasing Hormone
keywords: androgen-deprivation therapy; metabolic syndrome; prostate cancer